Rocket Pharmaceuticals (RCKT) EBITDA (2014 - 2026)
Rocket Pharmaceuticals (RCKT) posted EBITDA of -$48.5 million for Q1 2026, down 10.35% sequentially from -$44.0 million in Q4 2025, and up 24.66% YoY from -$38.9 million in Q1 2025.
Rocket Pharmaceuticals (RCKT) EBITDA (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported EBITDA for 13 years, with the latest figure at -$48.5 million in Q1 2026.
- Quarterly EBITDA rose 24.66% year-over-year to -$48.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$215.9 million (up 20.11% YoY) and the FY2025 annual result came in at -$231.7 million, up 15.17% from the prior year.
- EBITDA eased to -$48.5 million in Q1 2026 per RCKT's latest filing, from -$44.0 million in the prior quarter.
- Over five years, EBITDA peaked at -$42.6 million in Q1 2022 and troughed at -$73.7 million in Q2 2024.
- A 5-year average of -$61.0 million and a median of -$63.3 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA sank 59.22% in 2022, then grew 29.88% in 2025.
- Over 5 years, EBITDA stood at -$69.1 million in 2022, then increased by 8.4% to -$63.3 million in 2023, then climbed by 0.92% to -$62.7 million in 2024, then advanced by 29.88% to -$44.0 million in 2025, then dropped by 10.35% to -$48.5 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$48.5 million, -$44.0 million, and -$52.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Rocket Pharmaceuticals | 380.92 Mn | 380.92 Mn | - | -46.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46.92 Mn |
| Mar 31, 2026 | -48.51 Mn |
| Dec 31, 2025 | -43.96 Mn |
| Sep 30, 2025 | -52.25 Mn |
| Jun 30, 2025 | -71.15 Mn |
| Mar 31, 2025 | -64.39 Mn |
| Dec 31, 2024 | -62.69 Mn |
| Sep 30, 2024 | -69.42 Mn |
| Jun 30, 2024 | -73.71 Mn |
| Mar 31, 2024 | -67.38 Mn |
| Dec 31, 2023 | -63.28 Mn |
| Sep 30, 2023 | -65.43 Mn |
| Jun 30, 2023 | -68.76 Mn |
| Mar 31, 2023 | -62.19 Mn |
| Dec 31, 2022 | -69.08 Mn |
| Sep 30, 2022 | -58.49 Mn |
| Jun 30, 2022 | -54.21 Mn |
| Mar 31, 2022 | -42.56 Mn |
| Dec 31, 2021 | -44.33 Mn |
| Sep 30, 2021 | -49.65 Mn |